Clinicogenomic Analysis of <i>FGFR2</i> -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
- DOI
- 10.1158/2159-8290.cd-20-0766
- Published
- 2021-02-01
- Container
- Cancer Discovery
- Publisher
- American Association for Cancer Research (AACR)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1158/2159-8290.cd-20-0766,
title = {Clinicogenomic Analysis of
<i>FGFR2</i>
-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib},
author = {Ian M. Silverman and Antoine Hollebecque and Luc Friboulet and Sherry Owens and Robert C. Newton and Huiling Zhen and Luis Féliz and Camilla Zecchetto and Davide Melisi and Timothy C. Burn},
year = {2021},
journal = {Cancer Discovery},
doi = {10.1158/2159-8290.cd-20-0766},
url = {https://doi.org/10.1158/2159-8290.cd-20-0766}
}RIS
TY - JOUR
TI - Clinicogenomic Analysis of
<i>FGFR2</i>
-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
AU - Ian M. Silverman
AU - Antoine Hollebecque
AU - Luc Friboulet
AU - Sherry Owens
AU - Robert C. Newton
AU - Huiling Zhen
AU - Luis Féliz
AU - Camilla Zecchetto
AU - Davide Melisi
AU - Timothy C. Burn
PY - 2021
JO - Cancer Discovery
DO - 10.1158/2159-8290.cd-20-0766
UR - https://doi.org/10.1158/2159-8290.cd-20-0766
ER - APA
Silverman, I. M., Hollebecque, A., Friboulet, L., Owens, S., Newton, R. C., Zhen, H., Féliz, L., Zecchetto, C., Melisi, D., & Burn, T. C. (2021). Clinicogenomic Analysis of <i>FGFR2</i> -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-20-0766
Source records
- crossref · retrieved 2026-09-26T02:04:13.067Z